- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Mylan buys generic derm drugs from Valeant
Mylan has purchased a pair of generic dermatology products from Canadian drugmaker Valeant Pharmaceuticals International, the Associated Press reports.
Canonsburg, Pa. - Mylan has purchased a pair of generic dermatology products from Canadian drugmaker Valeant Pharmaceuticals International, the Associated Press reports.
Mylan officials say the company has acquired the rights to generic versions of Valeant’s BenzaClin (clindamycin 1 percent/benzoyl peroxide 5 percent), a topical acne treatment, and Efudex (fluorouracil 5 percent), a treatment for actinic keratosis. Terms of the deal were not disclosed.
Mylan already makes the generic version of BenzaClin through a licensing agreement, and the deal gives it the right to also make and sell an authorized generic version of Efudex.
Valeant was required to sell the drugs as part of its 2011 deal to buy Dermik, the dermatology division of French pharmaceutical firm Sanofi.
Go back to the Dermatology Times eNews newsletter.
